These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21498159)

  • 61. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
    Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
    Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Metabolic effects of GH antagonism in patients with acromegaly.
    Trainer PJ
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Insights from growth hormone receptor blockade.
    Muller AF; van der Lely AJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
    [TBL] [Abstract][Full Text] [Related]  

  • 64. USAN Council. List No.428. New names. Pegvisomant.
    Clin Pharmacol Ther; 2000 Jul; 68(1):106. PubMed ID: 10991628
    [No Abstract]   [Full Text] [Related]  

  • 65. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
    Drake WM; Parkinson C; Besser GM; Trainer PJ
    Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
    Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
    Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment of acromegaly].
    Dénes J; Korbonits M; Hubina E; Góth M
    Orv Hetil; 2010 Aug; 151(34):1384-93. PubMed ID: 20705553
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pegvisomant Pfizer/Sensus.
    Goffin V; Touraine P
    Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
    van der Lely AJ; Hutson RK; Trainer PJ; Besser GM; Barkan AL; Katznelson L; Klibanski A; Herman-Bonert V; Melmed S; Vance ML; Freda PU; Stewart PM; Friend KE; Clemmons DR; Johannsson G; Stavrou S; Cook DM; Phillips LS; Strasburger CJ; Hackett S; Zib KA; Davis RJ; Scarlett JA; Thorner MO
    Lancet; 2001 Nov; 358(9295):1754-9. PubMed ID: 11734231
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Drug therapy for acromegaly].
    Góth M
    Orv Hetil; 2013 Sep; 154(39):1527-34. PubMed ID: 24058097
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
    Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
    J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment strategies for acromegaly.
    Roelfsema F; Biermasz NR; Romijn JA; Pereira AM
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):875-90. PubMed ID: 16262568
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GH receptor antagonist: mechanism of action and clinical utility.
    Surya SK; Barkan AL
    Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New formulations and approaches in the medical treatment of acromegaly.
    Debono M; Newell-Price J
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.
    Drake WM; Berney DM; Kovacs K; Monson JP
    Eur J Endocrinol; 2005 Aug; 153(2):203-5. PubMed ID: 16061824
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Experience from the Argentine Pegvisomant Observational Study: preliminary data.
    García Basavilbaso N; Guitelman M; Nagelberg A; Stalldecker G; Carabelli A; Bruno O; Danilowitz K; Manavela M; Mallea Gil S; Ballarino C; Guelman R; Katz D; Fidalgo S; Leal R; Fideleff H; Servidio M; Bruera D; Librandi F; Chervin A; Vitale M; Basso A
    Front Horm Res; 2010; 38():42-49. PubMed ID: 20616494
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pegvisomant and improvement of quality of life in acromegalic patients.
    Neggers SJ; van der Lely AJ
    Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.